Hims & Hers Health, Inc. (NYSE:HIMS) Stock Position Cut by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. trimmed its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 26.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,856 shares of the company's stock after selling 8,753 shares during the period. Robeco Institutional Asset Management B.V.'s holdings in Hims & Hers Health were worth $705,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of HIMS. SlateStone Wealth LLC raised its holdings in shares of Hims & Hers Health by 4.0% during the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company's stock valued at $257,000 after buying an additional 413 shares during the period. Blume Capital Management Inc. grew its position in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after acquiring an additional 600 shares in the last quarter. Summit Investment Advisors Inc. raised its stake in shares of Hims & Hers Health by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company's stock valued at $480,000 after purchasing an additional 628 shares during the period. Cim LLC lifted its position in shares of Hims & Hers Health by 1.0% during the fourth quarter. Cim LLC now owns 71,869 shares of the company's stock worth $1,738,000 after purchasing an additional 694 shares in the last quarter. Finally, Harbour Investments Inc. grew its holdings in Hims & Hers Health by 18.8% during the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company's stock valued at $127,000 after purchasing an additional 833 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS traded up $0.46 during trading on Friday, reaching $47.92. The stock had a trading volume of 17,394,334 shares, compared to its average volume of 23,391,440. The firm's 50 day moving average price is $52.23 and its two-hundred day moving average price is $40.20. Hims & Hers Health, Inc. has a one year low of $13.47 and a one year high of $72.98. The stock has a market cap of $10.72 billion, a PE ratio of 69.44, a P/E/G ratio of 1.76 and a beta of 2.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.08. The business had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The business's revenue was up 110.7% on a year-over-year basis. During the same quarter last year, the business posted $0.05 EPS. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Activity

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of the business's stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $58.40, for a total transaction of $7,482,616.80. Following the completion of the transaction, the chief executive officer directly owned 89,311 shares of the company's stock, valued at $5,215,762.40. The trade was a 58.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Melissa Baird sold 33,337 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $27.32, for a total value of $910,766.84. Following the sale, the chief operating officer directly owned 805,083 shares in the company, valued at approximately $21,994,867.56. This trade represents a 3.98% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 692,006 shares of company stock valued at $34,857,872. 13.71% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

HIMS has been the topic of a number of recent analyst reports. Morgan Stanley reiterated an "equal weight" rating and issued a $40.00 price objective on shares of Hims & Hers Health in a report on Wednesday, June 11th. Bank of America lifted their target price on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research report on Tuesday, April 29th. Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Finally, Piper Sandler reaffirmed a "neutral" rating and issued a $39.00 target price (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $39.58.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.